$64.66 Million in Sales Expected for Tesaro (TSRO) This Quarter

Wall Street analysts predict that Tesaro (NASDAQ:TSRO) will announce $64.66 million in sales for the current quarter, Zacks reports. Nine analysts have made estimates for Tesaro’s earnings. The highest sales estimate is $77.77 million and the lowest is $56.47 million. Tesaro reported sales of $29.46 million in the same quarter last year, which indicates a positive year over year growth rate of 119.5%. The business is scheduled to issue its next quarterly earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that Tesaro will report full year sales of $308.16 million for the current financial year, with estimates ranging from $268.47 million to $324.00 million. For the next year, analysts expect that the business will report sales of $499.90 million per share, with estimates ranging from $444.68 million to $717.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Tesaro.

Tesaro (NASDAQ:TSRO) last posted its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.56) by ($0.42). Tesaro had a negative return on equity of 177.92% and a negative net margin of 193.42%. The firm had revenue of $49.74 million for the quarter, compared to analyst estimates of $56.34 million. During the same period in the previous year, the company posted ($2.55) EPS. Tesaro’s revenue was up 1520.2% on a year-over-year basis.

Several equities analysts recently issued reports on the company. Cann reissued a “buy” rating and set a $122.00 target price (down previously from $199.00) on shares of Tesaro in a research note on Tuesday, February 27th. Evercore ISI raised Tesaro from an “in-line” rating to an “outperform” rating and set a $88.00 target price on the stock in a research note on Thursday, February 22nd. Wells Fargo reissued an “outperform” rating and set a $122.00 target price (down previously from $224.00) on shares of Tesaro in a research note on Wednesday, February 28th. Leerink Swann reissued an “outperform” rating and set a $105.00 target price (down previously from $123.00) on shares of Tesaro in a research note on Wednesday, February 28th. Finally, HC Wainwright reissued a “buy” rating and set a $108.00 target price on shares of Tesaro in a research note on Tuesday, March 27th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and fifteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $119.00.

In other Tesaro news, Director David M. Mott acquired 68,302 shares of the company’s stock in a transaction dated Friday, March 2nd. The shares were acquired at an average price of $55.56 per share, for a total transaction of $3,794,859.12. Following the acquisition, the director now owns 12,825 shares in the company, valued at approximately $712,557. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Leon O. Moulder, Jr. acquired 5,000 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was acquired at an average price of $56.93 per share, for a total transaction of $284,650.00. Following the acquisition, the chief executive officer now owns 1,018,828 shares in the company, valued at approximately $58,001,878.04. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 334,913 shares of company stock worth $19,083,294 and have sold 13,042 shares worth $760,526. 33.70% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Neuberger Berman Group LLC increased its holdings in shares of Tesaro by 0.8% in the 1st quarter. Neuberger Berman Group LLC now owns 149,157 shares of the biopharmaceutical company’s stock valued at $8,523,000 after acquiring an additional 1,117 shares during the last quarter. Exane Derivatives increased its holdings in shares of Tesaro by 137.1% in the 4th quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 1,123 shares during the last quarter. Aperio Group LLC increased its holdings in shares of Tesaro by 29.9% in the 4th quarter. Aperio Group LLC now owns 4,922 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 1,132 shares during the last quarter. American International Group Inc. increased its holdings in shares of Tesaro by 138.8% in the 1st quarter. American International Group Inc. now owns 2,099 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 1,220 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Tesaro by 2.5% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 52,405 shares of the biopharmaceutical company’s stock valued at $2,994,000 after acquiring an additional 1,287 shares during the last quarter.

Tesaro opened at $47.71 on Friday, according to Marketbeat Ratings. Tesaro has a 12-month low of $44.76 and a 12-month high of $168.92. The company has a current ratio of 4.02, a quick ratio of 3.56 and a debt-to-equity ratio of 3.74. The stock has a market cap of $2.77 billion, a P/E ratio of -5.20 and a beta of 1.32.

About Tesaro

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Get a free copy of the Zacks research report on Tesaro (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tesaro (NASDAQ:TSRO)

Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply